选择性5-HT4受体激动剂与重性抑郁障碍发病率之间的关联:模拟目标试验
基于美国大型电子健康记录网络的模拟目标试验,比较无精神疾病史个体启用普芦卡必利与两种不影响中枢的便秘药后1年内重性抑郁障碍首发诊断。普芦卡必利组抑郁发生率显著低于利那洛肽组(HR 0.87,95%CI 0.76-0.99,P=0.038)和鲁比前列酮组(HR 0.79,95%CI 0.69-0.91,P<0.001),所有心境障碍和精神病风险也显著降低。
要点
- 普芦卡必利组1年内重性抑郁障碍首发风险低于利那洛肽组(HR 0.87,95%CI 0.76-0.99,P=0.038)。
- 普芦卡必利组1年内重性抑郁障碍首发风险低于鲁比前列酮组(HR 0.79,95%CI 0.69-0.91,P<0.001)。
- 所有心境障碍和精神病风险也显著降低,稳健性分析结果相似。
核心结论
- 研究结果支持临床前数据,提示5-HT4R激动剂可能作为预防重性抑郁的新型药物。
- 作者认为这些发现应推动随机对照试验,以确认此类药物能否在临床环境中作为新型抗抑郁药。
研究设计与样本
- 采用美国大型电子健康记录网络的匿名常规收集数据,开展模拟目标试验。
- 研究对象为无重性精神疾病既往诊断、启用普芦卡必利或两种不同机制抗便秘药(利那洛肽和鲁比前列酮)的个体。
- 队列按121个协变量进行匹配,涵盖社会人口学因素以及既往和/或并发疾病与用药。
- 主要结局为索引日期后1年内重性抑郁障碍(ICD-10编码F32)首次诊断。
主要发现
- 普芦卡必利组与利那洛肽组(各8572例匹配队列)比较,1年内抑郁发生率显著更低(HR 0.87,95%CI 0.76-0.99,P=0.038)。
- 普芦卡必利组与鲁比前列酮组(各8281例)比较,1年内抑郁发生率显著更低(HR 0.79,95%CI 0.69-0.91,P<0.001)。
- 所有心境障碍和精神病风险也显著降低。
- 各项稳健性分析结果相似。
关键数值与推荐
- 主要结局指标为索引日期后1年内重性抑郁障碍(ICD-10编码F32)首次诊断。
- 普芦卡必利对比利那洛肽:HR 0.87,95%CI 0.76-0.99,P=0.038,每组8572例。
- 普芦卡必利对比鲁比前列酮:HR 0.79,95%CI 0.69-0.91,P<0.001,每组8281例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The serotonin 4 receptor (5-HT4R) is a promising target for the treatment of depression. Highly selective 5-HT4R agonists, such as prucalopride, have antidepressant-like and procognitive effects in preclinical models, but their clinical effects are not yet established. AIMS: To determine whether prucalopride (a 5-HT4R agonist and licensed treatment for constipation) is associated with reduced incidence of depression in individuals with no past history of mental illness, compared with anti-constipation agents with no effect on the central nervous system. METHOD: Using anonymised routinely collected data from a large-scale USA electronic health records network, we conducted an emulated target trial comparing depression incidence over 1 year in individuals without prior diagnoses of major mental illness, who initiated treatment with prucalopride versus two alternative anti-constipation agents that act by different mechanisms (linaclotide and lubiprostone). Cohorts were matched for 121 covariates capturing sociodemographic factors, and historical and/or concurrent comorbidities and medications. The primary outcome was a first diagnosis of major depressive disorder (ICD-10 code F32) within 1 year of the index date. Robustness of the results to changes in model and population specification was tested. Secondary outcomes included a first diagnosis of six other neuropsychiatric disorders. RESULTS: Treatment with prucalopride was associated with significantly lower incidence of depression in the following year compared with linaclotide (hazard ratio 0.87, 95% CI 0.76-0.99; P = 0.038; n = 8572 in each matched cohort) and lubiprostone (hazard ratio 0.79, 95% CI 0.69-0.91; P < 0.001; n = 8281). Significantly lower risks of all mood disorders and psychosis were also observed. Results were similar across robustness analyses. CONCLUSIONS: These findings support preclinical data and suggest a role for 5-HT4R agonists as novel agents in the prevention of major depression. These findings should stimulate randomised controlled trials to confirm if these agents can serve as a novel class of antidepressant within a clinical setting.
引用
- de Cates AN, Harmer CJ, Harrison PJ, et al. Association between a selective 5-HT4 receptor agonist and incidence of major depressive disorder: emulated target trial. Br J Psychiatry. 2024. PMID: 39109752. doi:10.1192/bjp.2024.97
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。